Related Experiment Video
Updated: Feb 18, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib
Christos Sachpekidis1, Jessica C Hassel, Antonia Dimitrakopoulou-Strauss
1Medical PET Group-Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany. christos₋saxpe @yahoo.gr, c. sachpekidis@dkfz.de.
Abstract:
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

